Bio-Techne Corporation
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Bio-Techne Corporation's yearly results (2023–2026), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 7.2 times. Higher than 92% of Healthcare companies in United States.
- Debt Due Cover Ratio: Debt due within a year is covered 19.6 times by its yearly operating cash. Higher than 89% of Healthcare companies in United States.
- Growth Efficiency Ratio: Sales grew 7% in 3 years, but profit fell: $132 less profit per $100 of extra sales. Lower than 88% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Jun 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$208Over the last 3 years, every $100 of reported profit came with $208 of operating cash.
Higher than 78% of Healthcare companies in United States.
Self-Funding Ratio
7.2×Over the last 3 years its own operating cash covered its investment spending (capex) 7.2 times.
Higher than 92% of Healthcare companies in United States.
Cash Locked Ratio
$31For every $100 of sales, $31 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $31 tied up three years earlier.
More money tied up than 69% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Less steady than 51% of Healthcare companies in United States.
Growth Efficiency Ratio
−$132Sales grew 7% in 3 years, but profit fell: $132 less profit per $100 of extra sales.
Lower than 88% of Healthcare companies in United States.
Asset Productivity Ratio
+7% / -2%In 3 years sales changed by +7% while total assets changed by -2%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
19.6×Debt due within a year is covered 19.6 times by its yearly operating cash.
Higher than 89% of Healthcare companies in United States.
Cash Cushion Ratio
−0%Debt, after subtracting cash, equals 0% of its market value (net debt).
Lower than 68% of Healthcare companies in United States.
Tangible Assets Ratio
51%Of every $100 the company owns, $51 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 79% of Healthcare companies in United States.
Tangible Net Worth Ratio
39%Of every $100 of net worth, $39 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 59% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Bio-Techne Corporation owes $0.18 for every $1 it owns. Net profit rose 148% in the year to Jun 2026, and shrank 14% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Jun 2026.
P/E ratio
62.5Investors pay $62.5 for every $1 of Bio-Techne Corporation's yearly profit, higher than 84% of Healthcare companies in United States.
P/B ratio
5.40The share price is 5.40 times Bio-Techne Corporation's book value per share, higher than 74% of Healthcare companies in United States.
Market cap
$11.4 BThe total market value of all of Bio-Techne Corporation's shares at today's price (share price × number of shares), larger than 91% of Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$2.1 BWhat Bio-Techne Corporation would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$13.44Net worth divided by the number of shares. The share price of $72.55 is 5.4 times this, which is the P/B above.
Return on equity (ROE)
9.0%Bio-Techne Corporation earned 9.0% on its shareholders' money over the last year, higher than 82% of Healthcare companies in United States.
Owes vs Owns
0.18×Bio-Techne Corporation owes $0.18 for every $1 it owns (low), lower than 75% of Healthcare companies in United States.
Dividend yield
0.44%Bio-Techne Corporation pays 0.44% of its share price as dividends a year, lower than 82% of dividend-paying Healthcare companies in United States.
Revenue growth
-0%Revenue fell 0% in the year to Jun 2026, and grew 2% a year on average over 3 years.
Profit growth
+148%Net profit rose 148% in the year to Jun 2026, and shrank 14% a year on average over 3 years.
Profit margin
15.0%Bio-Techne Corporation keeps $15 of every $100 of revenue as net profit.
Cash quality
1.6×Cash from Bio-Techne Corporation's business was 1.6× its reported profit in the year to Jun 2026 — its profit turned into cash.
Interest cover
28.3×Bio-Techne Corporation's operating profit covered its interest costs 28.3 times in the year to Jun 2026.
Cash vs debt
Net debtBio-Techne Corporation had $24 M more debt than cash (net debt) at Jun 2026.
Questions
What is Bio-Techne Corporation's P/E ratio?
Investors pay $62.5 for every $1 of Bio-Techne Corporation's yearly profit, higher than 84% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Bio-Techne Corporation: $11.4 B ÷ $2.1 B (30 Jun 2026) = 5.4.
What is Bio-Techne Corporation's return on equity?
Bio-Techne Corporation earned 9.0% on its shareholders' money over the last year, higher than 82% of Healthcare companies in United States.
How much does Bio-Techne Corporation owe compared with what it owns?
Bio-Techne Corporation owes $0.18 for every $1 it owns (low), lower than 75% of Healthcare companies in United States.
Does Bio-Techne Corporation pay a dividend?
Yes. Bio-Techne Corporation pays 0.44% of its share price as dividends a year, lower than 82% of dividend-paying Healthcare companies in United States.
Is Bio-Techne Corporation's revenue growing?
Revenue fell 0% in the year to Jun 2026, and grew 2% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.